Mercaptopurine: Difference between revisions
m (Protected "Mercaptopurine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 19: | Line 19: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 48: | Line 48: | ||
<references/> | <references/> | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
[[Category:Immunosuppressive agents]] | [[Category:Immunosuppressive agents]] | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
Revision as of 17:19, 9 August 2012
| Error creating thumbnail: File missing | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 5 to 37% |
| Metabolism | ? |
| Elimination half-life | 60 to 120 min., longer for its active metabolites |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C5H4N4S |
| Molar mass | 152.181 g/mol |
|
WikiDoc Resources for Mercaptopurine |
|
Articles |
|---|
|
Most recent articles on Mercaptopurine Most cited articles on Mercaptopurine |
|
Media |
|
Powerpoint slides on Mercaptopurine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Mercaptopurine at Clinical Trials.gov Trial results on Mercaptopurine Clinical Trials on Mercaptopurine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Mercaptopurine NICE Guidance on Mercaptopurine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Mercaptopurine Discussion groups on Mercaptopurine Patient Handouts on Mercaptopurine Directions to Hospitals Treating Mercaptopurine Risk calculators and risk factors for Mercaptopurine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Mercaptopurine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Mercaptopurine (also called 6-Mercaptopurine, 6-MP or its brand name Purinethol) is an immunosuppressive drug used to treat leukemia. It is also used for pediatric non-Hodgkin's lymphoma, polycythemia vera, psoriatic arthritis, and inflammatory bowel disease (such as Crohn's Disease and ulcerative colitis).
Adverse reactions
Some of the adverse reactions of taking Mercaptopurine might include diarrhea, nausea, vomiting, loss of appetite, stomach/abdominal pain, weakness, skin rash, darkening of the skin, or hair loss. Serious adverse reactions include mouth sores, fever, sore throat, easy bruising or bleeding, pinpoint red spots on the skin, yellowing of eyes or skin, dark urine, painful or difficult urination. Unlikely but serious side effects include: black or tarry stools (melena), bloody stools, and bloody urine.
Symptoms of allergic reaction to Mercaptopurine include rash, itching, swelling, dizziness, trouble breathing.
Mercaptopurine causes myelosuppression, suppressing the production of white blood cells. It may be toxic to bone marrow. Weekly blood counts are recommended for patients on mercaptopurine. The patient should stop taking the medication at least temporarily if there is an unexplained, abnormally large drop in white blood cell count, or any other blood count.
Patients who exhibit myelosuppression or bone marrow toxicity should be tested for Thiopurine methyltransferase (TPMT) enzyme deficiency. Patients with TPMT deficiency are much more likely to develop dangerous myelosuppression. In such patients it may be possible to continue using mercaptopurine, but at a lower dose.
Precautions
Mercaptopurine can lower the body's ability to fight off infection. Those taking mercaptopurine should get permission from a doctor in order to receive immunizations and vaccinations. It is also recommended that while on the drug one should avoid those who have recently received oral polio vaccine.
This drug is traditionally not recommended during pregnancy but this issue has been debated and current evidence indicates that pregnant women on the drug show no increase in fetal abnormalities. However, women receiving mercaptopurine during the first trimester of pregnancy have an increased incidence of abortion. Davis et al 1999 found that mercaptopurine, compared to methotrexate, was ineffective as a single-agent abortifacient; every woman in the mercaptopurine arm of the study had fetal cardiac activity at follow-up (two weeks later) and was given a suction abortion.[1]
Mercaptopurine causes changes to chromosomes in animals and humans. In mice these changes have given rise to lethal mutations. Therefore the drug has the potential to be cancer causing in humans.
See also
References
- Pages with script errors
- Pages with citations using unsupported parameters
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Immunosuppressive agents
- Chemotherapeutic agents